Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for... Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's lead compound in development is AT-1501 which is the next generation anti-CD40L antibody. 더 보기
Completed enrollment of Phase 2 BESTOW trial of tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025 Announced positive...
IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.06 | -1.45278450363 | 4.13 | 4.17 | 3.76 | 291240 | 3.9138197 | CS |
4 | 0.5 | 14.0056022409 | 3.57 | 5.54 | 3.2 | 1013471 | 4.04389849 | CS |
12 | 1.18 | 40.830449827 | 2.89 | 5.54 | 2.375 | 390951 | 3.88916243 | CS |
26 | 0.97 | 31.2903225806 | 3.1 | 5.54 | 2.3 | 242572 | 3.61862827 | CS |
52 | 2.87 | 239.166666667 | 1.2 | 5.54 | 1.1099 | 185286 | 3.09270827 | CS |
156 | -1.22 | -23.0623818526 | 5.29 | 5.54 | 1.07 | 108379 | 2.87471401 | CS |
260 | -11.73 | -74.2405063291 | 15.8 | 22.91 | 1.07 | 98953 | 3.89739405 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관